Orphacol

cholic acid

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Orphacol. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Orphacol.

For practical information about using Orphacol, patients should read the package leaflet or contact their doctor or pharmacist.

What is Orphacol and what is it used for?

Orphacol is a medicine containing cholic acid, a substance found in the bile, which is used to digest fats.

It is used to treat adults and children from one month of age who have a genetic abnormality that makes them unable to produce bile. Orphacol is used in patients who do not have enough of two specific liver enzymes (3β-hydroxy-Δ5-C27-steroid oxidoreductase or Δ4-3-oxosteroid-5β-reductase). This makes their liver unable to produce enough of the main components of bile, called primary bile acids, such as cholic acid. When these primary bile acids are lacking, the body produces abnormal bile acids instead which can damage the liver, potentially leading to life-threatening liver failure.

Because the number of patients with inborn errors in primary bile acid synthesis is low, the condition is considered ‘rare’, and Orphacol was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 18 December 2002.

How is Orphacol used?

The medicine can only be obtained with a prescription and treatment with Orphacol should be started and supervised by a doctor specialised in liver disease.

Orphacol is available as capsules and should be taken every day at approximately the same time, with a meal. The daily dose is between 5 and 15 mg per kilogram body weight, adjusted for each patient according to the state of their bile acid, with a minimum daily dose of 50 mg and a maximum of 500 mg. For small children who cannot swallow capsules, the contents can be mixed in with infant formula or juice. Treatment should be stopped if liver function does not improve within three months.

How does Orphacol work?

Cholic acid is the main primary bile acid produced by the liver. The cholic acid contained in Orphacol replaces the patient’s missing cholic acid. This helps to decrease the production of abnormal bile acids and contributes to the normal activity of bile in the digestive system, thereby relieving the symptoms of the condition.

What benefits of Orphacol have been shown in studies?

Because cholic acid is a well known substance, and its use in these enzyme deficiencies is well established, the applicant presented data from the scientific literature. The applicant presented data on 49 patients with inborn errors in primary bile acid synthesis, taken from the scientific literature (38 patients with 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency and 11 patients with Δ4-3-oxosteroid-5β-reductase deficiency). It compared the outcomes of 28 patients who received cholic acid with others who were given different bile acids or did not receive bile-acid treatment.

In the scientific literature, cholic acid treatment was shown to reduce the amount of abnormal bile acids in patients, to restore the normal functions of the liver and to help delay or prevent the need for a liver transplant.

What are the risks associated with Orphacol?

The side effects seen with Orphacol were diarrhoea, pruritus (itching), increases in transaminases (liver enzymes) and possibly gallstones, although their frequency could not be reliably estimated from the available limited data.

Orphacol should not be used in people who may be hypersensitive (allergic) to cholic acid or any of the other ingredients. It must not be taken by patients already taking phenobarbital, a medicine used to treat epilepsy.

Why is Orphacol approved?

The Committee for Medicinal Products for Human Use (CHMP) noted that the use of cholic acid to treat inborn errors in primary bile-acid synthesis was well established in medical practice and documented in the scientific literature, although the number of documented cases was low due to the rarity of the condition. It decided that based on the evidence from the scientific literature, Orphacol’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Orphacol has been authorised under ‘exceptional circumstances’. This means that because the disease is rare, it has not been possible to obtain complete information about Orphacol. Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary.

What information is still awaited for Orphacol?

Since Orphacol has been approved under exceptional circumstances, the company that markets Orphacol will establish a database of patients treated with Orphacol to monitor the safety and effectiveness of the treatment, and will submit the results to the CHMP at regular, specified intervals.

What measures are being taken to ensure the safe and effective use of Orphacol?

A risk-management plan has been developed to ensure that Orphacol is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Orphacol, including the appropriate precautions to be followed by healthcare professionals and patients.

The company that makes Orphacol will also provide doctors in all Member States who will use Orphacol with a pack containing product literature and information regarding the correct diagnosis of these disease conditions, the risks of side effects and how to use the medicine properly.

Other information about Orphacol

The European Commission granted a marketing authorisation valid throughout the European Union for Orphacol on 12 September 2013.

For more information about treatment with Orphacol, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Orphacol : EPAR - Summary for the public BG = bălgarski 02/10/2013  
Orphacol : EPAR - Summary for the public ES = español 02/10/2013  
Orphacol : EPAR - Summary for the public CS = čeština 02/10/2013  
Orphacol : EPAR - Summary for the public DA = dansk 02/10/2013  
Orphacol : EPAR - Summary for the public DE = Deutsch 02/10/2013  
Orphacol : EPAR - Summary for the public ET = eesti keel 02/10/2013  
Orphacol : EPAR - Summary for the public EL = elliniká 02/10/2013  
Orphacol : EPAR - Summary for the public EN = English 02/10/2013  
Orphacol : EPAR - Summary for the public FR = français 02/10/2013  
Orphacol : EPAR - Summary for the public IT = italiano 02/10/2013  
Orphacol : EPAR - Summary for the public LV = latviešu valoda 02/10/2013  
Orphacol : EPAR - Summary for the public LT = lietuvių kalba 02/10/2013  
Orphacol : EPAR - Summary for the public HU = magyar 02/10/2013  
Orphacol : EPAR - Summary for the public MT = Malti 02/10/2013  
Orphacol : EPAR - Summary for the public NL = Nederlands 02/10/2013  
Orphacol : EPAR - Summary for the public PL = polski 02/10/2013  
Orphacol : EPAR - Summary for the public PT = português 02/10/2013  
Orphacol : EPAR - Summary for the public RO = română 02/10/2013  
Orphacol : EPAR - Summary for the public SK = slovenčina 02/10/2013  
Orphacol : EPAR - Summary for the public SL = slovenščina 02/10/2013  
Orphacol : EPAR - Summary for the public FI = suomi 02/10/2013  
Orphacol : EPAR - Summary for the public SV = svenska 02/10/2013  
Orphacol : EPAR - Summary for the public HR = Hrvatski 02/10/2013  

This EPAR was last updated on 10/12/2013 .

Authorisation details

Product details

Product details for Orphacol
NameOrphacol
Agency product numberEMEA/H/C/001250
Active substance

cholic acid

International non-proprietary name (INN) or common name

cholic acid

Therapeutic area Digestive System DiseasesMetabolism, Inborn Errors
Anatomical therapeutic chemical (ATC) code A05AA03
Additional monitoring

This medicine is under additional monitoring. This means that it is being monitored even more intensively than other medicines. For more information, see medicines under additional monitoring.

Treatment of rare diseases

This medicine has an "orphan designation" which means that it is used to treat life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in the European Union, or are medicines which, for economic reasons, would be unlikely to be developed without incentives.

Exceptional Circumstances

There were "exceptional circumstances" concerning the approval of this medicine. This happens when the applicant can show that they are unable to provide comprehensive data on the efficacy and safety of the medicine for which authorisation is being sought, due to the rarity of the condition it is intended for, limited scientific knowledge in the area concerned, or ethical considerations involved in the collection of such data.

Publication details

Publication details for Orphacol
Marketing-authorisation holder

Laboratoires CTRS

Revision1
Date of issue of marketing authorisation valid throughout the European Union12/09/2013

Contact address:

Laboratoire CTRS
69, rue d'Aguesseau
92100 Boulogne-Billancourt
France

Product information

Product information

11/11/2013  Orphacol -EMEA/H/C/001250 -IB/0001/G

Name Language First published Last updated
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013
Orphacol : EPAR - Product Information HR = Hrvatski 02/10/2013 10/12/2013

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  
Orphacol : EPAR - All Authorised presentations HR = Hrvatski 02/10/2013  

Name Language First published Last updated
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  
Orphacol : EPAR - Conditions imposed on member states for safe and effective use HR = Hrvatski 02/10/2013  

Pharmacotherapeutic group

Bile-acid preparations

Therapeutic indication

Orphacol is indicated for the treatment of inborn errors in primary bile-acid synthesis due to 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-oxosteroid-5β-reductase deficiency in infants, children and adolescents aged one month to 18 years and adults.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Orphacol : EPAR - Procedural steps taken and scientific information after authorisation HR = Hrvatski 10/12/2013  

Initial marketing-authorisation documents

Name Language First published Last updated
Orphacol : EPAR - Public assessment report HR = Hrvatski 02/10/2013  
CHMP summary of positive opinion for Orphacol HR = Hrvatski 17/12/2010  

Authorised

This medicine is approved for use in the European Union

Related information